Puma Biotechnology | PBYI - Sales Revenues


Puma Biotechnology reported $80.54M in Sales Revenues for its fiscal quarter ending in September of 2024.





Sales Change Date
Agios Pharmaceuticals USD 19.97M 7.07M Dec/2025
Alnylam Pharmaceuticals USD 1.1B 150M Dec/2025
Amgen USD 9.9B 340M Dec/2025
Biogen USD 2.28B 250M Dec/2025
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Daiichi Sankyo JPY 558.11B 57.35B Dec/2025
Esperion Therapeutics USD 168.45M 81.14M Dec/2025
Exelixis USD 598.66M 860K Dec/2025
Gilead Sciences USD 7.93B 130M Dec/2025
Glaxosmithkline GBP 11.46B 59.16M Dec/2025
Incyte USD 1.51B 140M Dec/2025
MacroGenics USD 41.23M 31.61M Dec/2025
Moderna USD 678M 342M Dec/2025
Novartis USD 13.86B 50M Dec/2025
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.88B 130M Dec/2025
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Takeda JPY 1.19T 80B Dec/2025
TG Therapeutics USD 192.57M 30.87M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
Vanda Pharmaceuticals USD 198.77M 151.12M Dec/2024
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025